Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9468144 | 0.91 | NPSR1 (0.42) | NPSR1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL28313838 | 0.89 | NPSR1 (0.33) | NPSR1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL2152795 | 0.85 | — | — | |
| SCHEMBL203079 | 0.82 | AKR1C1 (0.30) | — | |
| SCHEMBL27842294 | 0.81 | — | — | |
| Acetic Acid SCHEMBL27533339 | 0.81 | CYP3A4 (0.32) | CYP3A4 | |
| Bromide SCHEMBL689745 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL689891 | 0.81 | — | — | |
| Propane SCHEMBL1984333 | 0.79 | FFAR3 (0.30) | — | |
| SCHEMBL27836840 | 0.79 | TSHR (0.35) | NPSR1CYP3A4MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710710-A | Method for producing propylene polymer | 住友化学株式会社 | 2021-11-26 | — | — | CN | disclosed |
| CN-108658762-B | Synthesis method of alicyclic o-diester | 浙江凯普化工有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-108083978-B | Process and apparatus for the preparation of cyclohexanedimethanol | 万华化学集团股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-110382574-A | Heterophasic propylene polymeric material and Propenes resin composition | 住友化学株式会社 | 2019-10-25 | — | — | CN | disclosed |
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-18 | — | — | US | disclosed |
| CN-109563324-A | Heterophasic propylene polymeric material | 住友化学株式会社 | 2019-04-02 | — | — | CN | disclosed |
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| CN-108083978-A | The preparation process and device of cyclohexanedimethanol | 万华化学集团股份有限公司 | 2018-05-29 | — | — | CN | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| CN-107011339-A | Method and intermediate for the macrocyclic protease inhibitor for preparing HCV | 杨森制药公司 | 2017-08-04 | — | — | CN | disclosed |
| EP-2758386-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041655-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2547645-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | disclosed |
| WO-2011113859-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7858737-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-6958384-B2 | Polypeptides containing γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040116654-A1 | Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids | NATIONAL SCIENCE FOUNDATION | 2004-06-17 | — | — | US | disclosed |
| US-20030211999-A1 | Polypeptides containing gamma-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | DNPEP, PRKCSH, BCAT1 | NPSR1 3070/4885CYP3A4 4528/4885MEN1 2908/4885 |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | DNPEP, PRKCSH, YWHAZ | NPSR1 3184/4885CYP3A4 4492/4885MEN1 2992/4885 |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | NPSR1 251/4885CYP3A4 227/4885MEN1 3500/4885 |
| US-20030211999-A1 | Polypeptides containing gamma-amino acids | PEPD, DNPEP, ANPEP | NPSR1 515/4885CYP3A4 4557/4885MEN1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.